AI Search Summary
This video explains the FDA approval context for Spravato, the esketamine nasal spray, as a monotherapy for treatment-resistant depression after two oral antidepressants have failed. It distinguishes ketamine from esketamine, explains why placebo controls are difficult for dissociative drugs, and critiques the patent and pricing incentives around branded esketamine versus cheaper generic ketamine.
- Main question: Is the FDA approval of ketamine or esketamine as a monotherapy for depression a significant development?
- Short answer / core takeaway: The video treats Spravato/esketamine monotherapy approval as a meaningful step for treatment-resistant depression, while raising concerns about cost, patentability, study design, side effects, abuse potential, and limited independent testing of cheaper alternatives.
- Evidence type: Science-news explainer based on FDA/J&J approval context and study claims described in the transcript.
- Search topics: Spravato monotherapy approval, esketamine depression, ketamine treatment-resistant depression, FDA REMS, Johnson & Johnson Spravato, ketamine versus esketamine.
Common Search Questions
What changed with Spravato approval?
The transcript says doctors can prescribe Spravato by itself, without another oral antidepressant, for patients with depression who have already tried two oral antidepressants that did not work.
What is the difference between ketamine and esketamine?
The video explains that ketamine contains right- and left-handed molecular versions, while esketamine is the S version. Spravato is the branded nasal-spray form of esketamine.
Why is placebo control difficult in ketamine or esketamine trials?
The creator says trials are difficult to blind because the treatment has dissociative or psychedelic-like effects, making it hard for participants or clinicians not to notice which group someone is in.
Key Takeaways
- Ketamine has been used as an anesthetic in the U.S. since 1970.
- Esketamine, marketed as Spravato, was first FDA-approved in 2019 for treatment-resistant depression alongside an oral antidepressant.
- The video discusses a later approval allowing Spravato to be used as monotherapy under specific conditions.
- Spravato still requires clinical monitoring and a risk evaluation and mitigation strategy program because of side effects and abuse potential.
- The creator argues that patent incentives can favor expensive branded versions over cheaper compounds that may deserve independent trials.
Transcript
The new approval question
Ketamine for depression is now approved by the FDA as a monotherapy after the results of a new study. But is this a big deal? Here’s what you need to know.
Ketamine has been used in the U.S. as an anesthetic since 1970, being especially useful because it helps the brain dissociate from pain without stopping our breathing, which many other anesthetics do.
And it’s also been used recreationally, illegally, for its hallucinogenic effects, dubbed Special K, or just K. Warning: it’s low in fiber.
Ketamine versus esketamine
Ketamine itself is a combination of right- and left-handed versions of the same molecule, which us nerds call S and R versions.
Back in 2019, the FDA approved a nasal spray of just the S version for use in treatment-resistant depression, only when used alongside an oral antidepressant. It’s called esketamine, brand name Spravato.
Johnson & Johnson would say that this S version is more potent than the normal stuff because it has a stronger inhibiting effect on NMDA receptors in the brain.
Mechanism, potency, and trial limitations
I love how they confidently state in their press release that Spravato is unique and works by targeting glutamate, which is the most abundant excitatory neurotransmitter in the brain, while the mechanism by which esketamine exerts its antidepressant effect is unknown.
And a recent meta-analysis found normal ketamine to be a more potent antidepressant than esketamine. But that was IV ketamine versus a nasal spray.
And all of these trials have a big problem, which is that they can’t really do a placebo control when the main therapy is a psychedelic drug.
But we know that esketamine is much better at one thing: being patentable, which lets them charge $600 to $900 per dose. Twice a week, that adds up. Sales of $780 million in the first nine months of 2024.
What the new study reported
So what just changed? Last month, J&J submitted data from a new study to the FDA, where patients with major depression took Spravato, but this time without any other oral antidepressant.
They say that patients started experiencing improvements in their depressive symptoms within 24 hours, and improvements across all symptom categories by day 28, where 22.5% of them achieved complete remission from depression, compared to 7.6% in the placebo.
What monotherapy still requires
All the need for a daily antidepressant. All it takes is twice a week where you don’t eat for two hours, you go to a clinic, trip for a couple hours while being monitored, then get someone else to drive you home.
So this new FDA approval allows doctors to prescribe Spravato all by itself, without any other antidepressants in the mix, so long as they’ve already tried two oral antidepressants and they didn’t work.
But you have to qualify through a special risk evaluation and mitigation strategy program because of the side-effect risk and potential for abuse.
Bigger-picture funding critique
Overall, this is for mental illnesses, and this is a good step. And yes, it’s hard to run expensive trials without any sort of promise of a payoff.
I just wish we could get more independent funding to test the cheap versions of these compounds so we can actually get them out to all the millions of people who need them. I’ll keep you updated.
Additional Notes
Caption context
The caption points toward the possibility of another compound with similar promise but fewer side effects or lower abuse potential. It does not list a specific source or study citation.
Keywords and topics
- Spravato monotherapy
- Esketamine nasal spray
- Ketamine and depression
- Treatment-resistant depression
- FDA REMS program
- NMDA receptors and glutamate
- Patent incentives and drug pricing
References
- FDA/J&J Spravato monotherapy approval and supporting study are discussed in the transcript; source URL, DOI, and PMID were not listed in the workbook.
- Earlier meta-analysis comparing ketamine and esketamine is mentioned in the transcript; title, source URL, DOI, and PMID were not listed in the workbook.